Multiple myeloma, B-cell maturation antigen, BCMA, anti-BCMA, BCMA-directed, chimeric antigen receptor, CAR-T, PHE885
Showing 1 - 25 of >10,000
Multiple Myeloma Trial in Chicago, Boston, Milwaukee (PHE885)
Recruiting
- Multiple Myeloma
- PHE885
-
Chicago, Illinois
- +4 more
Jul 28, 2022
Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in San Francisco (Manufactured Anti-BCMA CAR-T cells, Fludarabine,
Recruiting
- Refractory Multiple Myeloma
- Relapsed Multiple Myeloma
- Manufactured Anti-BCMA CAR-T cells
- +2 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Jan 6, 2023
Multiple Myeloma Trial in Worldwide (PHE885)
Recruiting
- Multiple Myeloma
- PHE885
-
VIC, Melbourne, Australia
- +4 more
Jul 20, 2022
Relapsed/ Refractory Multiple Myeloma Trial (GC012F)
Not yet recruiting
- Relapsed/ Refractory Multiple Myeloma
- GC012F
- (no location specified)
Apr 28, 2023
Immunotherapy, Multiple Myeloma Trial in Zhengzhou (Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK))
Recruiting
- Immunotherapy
- Multiple Myeloma
- Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital
Dec 14, 2022
Refractory Multiple Myeloma, Relapse Multiple Myeloma Trial in Milwaukee (Belantamab mafodotin)
Recruiting
- Refractory Multiple Myeloma
- Relapse Multiple Myeloma
- Belantamab mafodotin
-
Milwaukee, WisconsinFroedtert & the Medical College of Wisconsin
Aug 3, 2022
Kidney Transplant, Kidney Failure, Highly Sensitized Trial in Boston, New York, Philadelphia (Cyclophosphamide, CART-BCMA,
Not yet recruiting
- Kidney Transplant
- +2 more
- Cyclophosphamide
- +3 more
-
Boston, Massachusetts
- +2 more
Sep 20, 2023
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (biological, drug, procedure)
Completed
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 3, 2022
Multiple Myeloma, Relapse Multiple Myeloma Trial in Ramat Gan (CAR-BCMA)
Recruiting
- Multiple Myeloma
- Relapse Multiple Myeloma
- CAR-BCMA
-
Ramat Gan, IsraelChaim Sheba Medical Center, Tel Hashomer
Feb 7, 2022
Multiple Myeloma Trial in Houston (Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A))
Not yet recruiting
- Multiple Myeloma
- Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)
-
Houston, TexasThe University of Texas MD Anderson Cancer Center
Jan 13, 2023
Multiple Myeloma, Smoldering Multiple Myeloma Trial in Boston (Ciltacabtagene Autoleucel, Cyclophosphamide, Fludarabine
Not yet recruiting
- Multiple Myeloma
- Smoldering Multiple Myeloma
- Ciltacabtagene Autoleucel
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Mar 2, 2023
Multiple Myeloma, Allogeneic Stem Cell Transplantation Trial in Spain (CARTemis-1)
Not yet recruiting
- Multiple Myeloma
- Allogeneic Stem Cell Transplantation
- CARTemis-1
-
Santander, Cantabria, Spain
- +4 more
Aug 1, 2023
Multiple Myeloma Trial in Bethesda, Oklahoma City, Fairfax (Descartes-08, Fludarabine, Cyclophosphamide)
Completed
- Multiple Myeloma
- Descartes-08
- +2 more
-
Bethesda, Maryland
- +2 more
Mar 10, 2022
Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma Trial in Dresden (MDC-CAR-BCMA001 (BCMA directed CAR
Not yet recruiting
- Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma
- MDC-CAR-BCMA001 (BCMA directed CAR T-cells)
-
Dresden, GermanyTechnische Universität Dresden, NCT/UCC, Early Clinical Trial Un
Apr 19, 2023
Multiple Myeloma Trial in New York (EGFRt/BCMA-41BBz CAR T cell, Cyclophosphamide, Lenalidomide.)
Active, not recruiting
- Multiple Myeloma
- EGFRt/BCMA-41BBz CAR T cell
- +2 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Mar 7, 2022
ITP Trial in Suzhou (autologous anti-BCMA chimeric antigen receptor T cells)
Recruiting
- ITP
- autologous anti-BCMA chimeric antigen receptor T cells
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Mar 31, 2022
Recurrent Multiple Myeloma, Refractory Multiple Myeloma Trial in Los Angeles (procedure, drug, other)
Not yet recruiting
- Recurrent Multiple Myeloma
- Refractory Multiple Myeloma
- Bone Marrow Aspiration
- +10 more
-
Los Angeles, CaliforniaMelanie Ayala Ceja
Jul 10, 2023
Multiple Myeloma Trial in China (LCAR-B38M CAR-T Cell)
Recruiting
- Multiple Myeloma
- LCAR-B38M CAR-T Cell
-
Beijing, Beijing, China
- +7 more
Dec 30, 2021
Multiple Myeloma Trial in Shanghai (Anti-BCMA CAR-T cells, Fludarabine, Cyclophosphamide)
Recruiting
- Multiple Myeloma
- Anti-BCMA CAR-T cells
- +3 more
-
Shanghai, Shanghai, ChinaShanghai Changzheng Hospital
Aug 29, 2021
Multiple Myeloma Trial in Japan, United States (JNJ-68284528)
Completed
- Multiple Myeloma
- JNJ-68284528
-
Phoenix, Arizona
- +20 more
Oct 5, 2022
Multiple Myeloma, Plasma Cell Tumor, Malignant Plasma Cell Tumor Trial in Houston (Radiation Therapy)
Recruiting
- Multiple Myeloma
- +2 more
- Radiation Therapy
-
Houston, TexasM D Anderson Cancer Center
Jul 9, 2022
Multiple Myeloma Trial in Beijing, Suzhou (CAR-BCMA T Cells)
Recruiting
- Multiple Myeloma
- CAR-BCMA T Cells
-
Beijing, Beijing, China
- +1 more
Jan 26, 2023
Multiple Myeloma Trial in Suzhou (clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells)
Recruiting
- Multiple Myeloma
- clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Oct 22, 2021
Multiple Myeloma Trial in Nashville (Cevostamab, Tocilizumab)
Recruiting
- Multiple Myeloma
-
Nashville, TennesseeTennessee Onc., PLLC - SCRI
Sep 8, 2022
Multiple Myeloma Trial in Hefei, Changzhou, Nanjing (Fully human BCMA chimeric antigen receptor autologous T cell injection
Not yet recruiting
- Multiple Myeloma
- Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)
-
Hefei, Anhui, China
- +3 more
Jan 3, 2022